Health Affairs, Drug Pricing Lab, Commonwealth Fund 07/24/2017

DPL and Collaborators to Publish Drug Pricing Primer Series

The Drug Pricing Lab and Commonwealth Fund are partnering with Health Affairs to create a series of educational primers on key topics in U.S. drug pricing.

The Drug Pricing Lab and Commonwealth Fund have partnered with Health Affairs to develop a 12-part series of educational primers on drug pricing issues in the United States. The comprehensive set of primers, along with three policy proposals for solutions to these issues, will be released in Health Affairs in fall 2017. The twelve primers of the series are available at the links below.

Expedited Approval Pathways

Pricing Orphan Drugs

Biosimilars

Patent Settlements

Medicare Part B

Medicare Part D

Medicaid Best Price

Veteran’s Health Administration

340B Drug Discount Program

Patient Financial Support

Formularies

Pharmacy Benefit Managers

Share
Related Issues
Abuses of Government Programs and Regulations Balancing Innovation and Drug Pricing Supply Chain Economics Favor Higher Cost Drugs Profitability over Public Health and Innovation
Related News
CNBC 10/12/2016

Copay Assistance: Doing More Harm Than Good?

The New York Times 03/10/2016

Medicare Tries an Experiment to Fight Perverse Incentives

The Washington Post 05/03/2017

Louisiana Revisits an Old Law to Address Drug Pricing

Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

Explore Our Research
Reports
Xeljanz, the FDA, and nine years of patient harm
Quantifying population-level adverse events in the near decade between when safety concerns were identified and FDA action
Drug Pricing Lab 05/31/2022
Reports
Atypical antipsychotics: Decades of use, unfathomable harms
Using attributable risk calculations to quantify how many premature deaths resulted from atypical antipsychotic use in the elderly
Drug Pricing Lab 05/31/2022
Reports
Medicare Part B Premium Dynamics Explained
The Drug Pricing Lab commissioned Milliman to prepare a report exploring the impact of changes in Medicare Part B program costs on beneficiaries’ premiums and Social Security payments. This report focuses on the 2022 Part B premium for beneficiaries with various income levels to illustrate the payment dynamics and discusses the implications for related programs.
Milliman 12/23/2021
Reports
Comparing Factors that Influence Pharmaceutical Pricing and Access in the…
Drug prices in the United States are some of the highest in the world, which has triggered several policy proposals aimed at adopting pricing strategies used by other countries.
Drug Pricing Lab 12/20/2021
Reports
Biosimilars in Medicare Part D: pricing dynamics and considerations
The Drug Pricing Lab engaged Milliman to prepare a report summarizing the pricing dynamics affecting utilization of biosimilars in the current Medicare Part D marketplace and under the proposed Part D benefit design in the Build Back Better Act.

This report was commissioned by the Drug Pricing Lab.
Milliman 12/14/2021
Reports
Evaluating Industry’s Drug Pricing Claims
A closer look at three of PhRMA’s most cited talking points.
Drug Pricing Lab 11/18/2021
Mapping conflict of interests: scoping review
A scoping review of the literature to identify all known ties between the medical product industry and the parties and activities in the healthcare ecosystem.
Drug Pricing Lab 11/03/2021
Reports
Production Plus Profit Pricing (P-quad) FAQ
08/17/2021
Academic Literature
What A Waste! The National Academy Of Medicine’s Report On…
Why Congress should not follow the National Academy of Science, Engineering, and Medicine’s recommendation to remove the JW modifier.
Health Affairs Blog 07/09/2021
Articles
Medicare Must Study Unproven, Expensive Alzheimer’s Drug
Medicare cannot indiscriminately cover the cost of Aduhelm for the treatment of Alzheimer's disease without first evaluating whether it truly works.
Bloomberg Opinion 06/15/2021
Academic Literature
Value-Based Management of Specialty Drugs: Practical Considerations and Implications for…
Not all approaches are suited to meeting policy makers and health plans’ goals of managing specialty drugs based on their value. Researchers conducted a qualitative study with Blue Cross Blue Shield plans interested in implementing value-based specialty pharmacy management to observe the plans’ objectives, strategies, and factors influencing their ability to execute on these strategies.
AJMC 05/13/2021
Articles
Trump's Drug-Pricing Ideas Would Cost Taxpayers a Bundle
Meanwhile, pharmaceutical companies would stand to make a lot more money.
Bloomberg Opinion 09/29/2020
Explore Our Research
Newsletter

Stay up to date on our work and news